{"id":64924,"name":"ARDELYX","slug":"ardelyx","state":"MA","country":"United States of America","description":"BioPharma Company","totalSpending":200000,"filings":5,"yearlySpending":[{"year":2025,"income":200000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"}],"firms":["THE MCMANUS GROUP"],"lobbyists":["JOHN MCMANUS"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Office of Management & Budget (OMB)","Health & Human Services, Dept of (HHS)"],"sampleDescriptions":["Payment for drugs for patients with end stage renal disease","Issues related to the 2025 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule (CMS-105-F), specifically the inclusion of oral-only drugs in the ESRD PPS Bundled Payment.","Issues related to the 2025 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule (CMS-105-F), specifically the inclusion of oral-only drugs in the ESRD PPS Bundled Payment.","Issues related to the 2025 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule (CMS-105-F), specifically the inclusion of oral-only drugs in the ESRD PPS Bundled Payment.","Issues related to the 2025 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule (CMS-105-F), specifically the inclusion of oral-only drugs in the ESRD PPS Bundled Payment. H.R.62"]}